What 'point-of-care' means in practice

On the day of a Mytocel MSK procedure, the patient arrives at the clinic and leaves having completed the full treatment. Between those two moments, a small sample of cartilage — three seed-sized biopsies taken from the back of the ear — is collected, processed, and administered to the affected joint, all within a single planned outpatient visit. No sample is sent to an external laboratory. No cell culture is started. No storage interval separates the moment of harvest from the moment of administration.

That unbroken chain — from ear to joint, entirely within one clinical setting — is what 'point-of-care' means in the context of Mytocel MSK. The patient's own tissue is prepared chairside using a compact mechanical device, and the resulting suspension is ready for infiltration within minutes. Because no step occurs outside the room, the biological material remains autologous in the most direct sense: it has not been handled by a third-party facility, altered by culturing conditions, or held in storage. The procedure's integrity rests on this architecture, and so does its regulatory classification as a minimal-manipulation, one-step intervention.

Why the posterior ear is the starting point

Posterior auricular cartilage provides a small, accessible autologous donor source. It is elastic cartilage and is not identical to the hyaline cartilage found on joint surfaces; the rationale for its use comes from cartilage-derived cellular and matrix-associated components and the supporting preclinical and early clinical evidence, not from treating the two tissues as interchangeable.

Three samples, each taken with a 2.5 mm dermal punch, are all the protocol requires. The footprint at the back of the ear is deliberately minimal. The protocol does not require sutures and describes healing over roughly one to two weeks, although individual healing and visible scarring can vary. Preliminary in vitro data confirm that the disaggregation process preserves cell viability and chondrogenic potential, so what is collected is biologically active rather than simply representative of the source tissue.

Because the material comes directly from the patient — not from a donor bank, a synthetic preparation, or a laboratory-grown product — it is described as autologous. This word carries meaningful clinical weight: the patient's immune system recognises the tissue as its own, reducing donor-compatibility concerns associated with allogeneic material. Autologous use is also one of the four regulatory pillars that place the Mytocel MSK procedure within the minimal-manipulation framework, alongside one-step surgery, minimal handling, and the monofunctional tissue match described above.

The disaggregation step: mechanical, controlled, chairside

Once the three auricular biopsies are collected, they are placed inside the sterile, single-use Rigeneracons® RS with approximately 4 mL of physiological saline. The Mytocel-specific protocol uses a motorised unit to run a six-minute mechanical disaggregation cycle, preparing micrograft particles without enzymatic digestion or ex-vivo culture. Device operation and exact settings must follow the current manufacturer instructions.

That distinction carries practical weight. Enzymatic or heat-based disaggregation can alter cellular membranes and degrade the extracellular matrix; controlled mechanical separation at a precise cut-off preserves both. This is the approach that supports the 'minimal manipulation' regulatory classification: the tissue is processed, but its biological character — chondrocytes embedded in matrix — is not fundamentally changed by the method itself.

The Mytocel-specific disaggregation cycle runs for six consecutive minutes. The output is the AMT® (Autologous Micrograft Technology) suspension: a turbid solution containing the micrograft particles, their associated trophic factors, and the supporting extracellular matrix. Turbidity is the chairside quality indicator that disaggregation has been successful — a clear solution signals a problem; white fibrous 'ghost tissue' remaining on the grid is discarded. Once drawn up, the suspension is ready for intra-articular infiltration within the same session.

The Rigeneracons® RS is opened sterile and discarded after one use, ensuring consistent microblade geometry and eliminating cross-contamination risk at every procedure. Because the Sicurdrill® 2.0 is portable and requires no fixed laboratory infrastructure, the processing step is genuinely room-agnostic — a further reason the workflow remains contained within the clinical setting.

How biological integrity is maintained across the workflow

The processing step delivers more than a particle suspension. In vitro work has confirmed that Rigenera® Technology's mechanical disaggregation leaves the extracellular matrix (ECM) scaffold intact and chondrocyte viability unaffected — the cellular architecture that gives cartilage its structural and biological character survives the controlled preparation cycle. Flow cytometry of the resulting AMT® suspension has identified CD44+ and CD117+ cell populations: surface markers associated with mesenchymal progenitor cells, meaning cells capable of paracrine signalling are present alongside structural matrix material, not merely inert debris.

The suspension also carries measurable concentrations of two trophic factors central to cartilage biology. Mean TGF-β content across samples was 81.4 pg/mL (SD ± 88.2 pg/mL) and mean IGF-1 was 676.3 pg/mL (± 212 pg/mL). IGF-1 is a well-characterised driver of chondrocyte survival and matrix synthesis; TGF-β supports cartilage homeostasis and carries immunomodulatory properties relevant to inflamed joint environments. The wider spread in TGF-β values reflects normal biological individuality between donors — an expected feature of any autologous preparation — while IGF-1 was relatively consistent across the sample set.

Collagen phenotyping adds a further layer of confirmation. Cells in the micrograft suspension test negative for type I collagen — the hallmark of fibrous or scar-like tissue — while type II collagen and aggrecan expression are maintained. In plain terms, the processing preserves the molecular signature of cartilage rather than converting chondrocytes towards a scar-forming fate. Animal-model immunohistochemical analyses have additionally identified chondrocyte islets embedded within ECM in treated defect areas, suggesting the micrografts retain organisational properties following delivery.

Each of these findings — cell viability data from in vitro studies, trophic factor assays, collagen phenotyping, and animal-model histology — represents a distinct evidence category. Their alignment builds a mechanistically coherent case for biological integrity across the point-of-care workflow. Clinical translation in a defined knee osteoarthritis population, as investigated prospectively by Tsoukas et al. in Bioengineering (2023), is the active next step in extending that foundation.

Bedside quality checks built into the protocol

Three defined checks are built directly into the protocol to confirm that what reaches the joint is a viable micrograft suspension — no external facility required.

The first is a visual turbidity assessment. Once the Rigeneracons® RS cycle is complete, the practitioner inspects the collected AMT® solution: a turbid appearance confirms that micrograft particles are present. A clear solution indicates insufficient disaggregation and is a protocol-level fail criterion — the preparation should not proceed to infiltration.

The second is identification and removal of white fibrous material, termed 'ghost tissue', which may remain on the device grid after disaggregation. This non-viable fraction is discarded before the suspension is drawn up, ensuring only the micrograft-containing solution is administered.

The third is structural rather than visual: because the Rigeneracons® RS is a sterile, single-use disposable, each procedure begins with intact, calibrated microblades at a verified 80 µm geometry. Resterilisation is prohibited by the protocol — blade integrity cannot be confirmed after one use — meaning the device design itself enforces consistency and eliminates cross-contamination risk as a matter of standard operating procedure rather than individual diligence.

Together, these steps embed quality assurance within the session workflow, keeping accountability with the treating clinician at the point of care.

Why the single-session design matters clinically

The workflow decisions described throughout this article — one session, no culture, mechanical disaggregation, auricular-to-articular delivery — carry a regulatory consequence with direct practical relevance for clinicians.

Regulatory classification depends on jurisdiction

Mytocel MSK is designed around autologous use, point-of-care preparation and minimal manipulation. Its exact regulatory classification and the requirements for clinical use depend on the jurisdiction, so clinics must follow local rules and the current manufacturer instructions rather than treating one classification statement as universal.

Clinical evidence in a defined population

The strongest direct evidence comes from a prospective observational study by Tsoukas et al. (Bioengineering, 2023, DOI: 10.3390/bioengineering10111294). The study included 10 patients aged 37–84 with Kellgren–Lawrence grade 2–3 knee OA — the population where joint preservation is the active clinical priority — assessing outcomes using KOOS and imaging. Results supported efficacy and safety in this cohort, with no severe adverse events. The limitations are those expected at this evidence stage: a small sample, no control arm, and a follow-up window that does not yet capture long-term durability; the authors identified randomised controlled trials as the necessary next step. The broader protocol lineage — drawing on Svolacchia (2016), Gentile (2017), and Marcarelli (2021) — places Rigenera® Technology within a peer-reviewed context across specialties, with each study's findings attributed to its own population and tissue.

The 2023 prospective observational study shows that this point-of-care autologous cartilage micrograft procedure was associated with improved KOOS outcomes in a small early-stage knee osteoarthritis cohort. Together with preclinical and protocol evidence, that supports further evaluation of Mytocel MSK while keeping claims proportional to the current evidence.